Announcement time of this financial report: 2023-10-25 18:30:26
Shuanglu Pharmaceutical Co., Ltd. (stock code: 002038) is a pharmaceutical biotechnology enterprise specializing in the research, development, production and management of genetic engineering and related drugs. The company's main business covers the fields of oncology, cardio-cerebrovascular, endocrine, liver disease, nephropathy, anti-infection and wound repair, and has multiple production bases, including tablets, hard capsules, granules, injections, freeze-dried powder injections, biochemical raw materials, therapeutic biological products, psychotropic drugs and other product categories.
In terms of assets and liabilities, Shuanglu Pharmaceutical's assets totaled 6.068 billion yuan in the third quarter of 2023, up from 5.876 billion yuan at the end of last year. The total liabilities were 375 million yuan, down from 397 million yuan at the end of last year. The net asset was 5.693 billion yuan, an increase compared with 5.479 billion yuan at the end of last year. The asset-liability ratio was 6.18%, down from 6.75% at the end of the previous year.
In terms of profit, Shuanglu Pharmaceutical's operating income in the third quarter of 2023 was 777 million yuan, down from 827 million yuan in the same period last year. The operating profit was 345 million yuan, up from 250 million yuan in the same period last year. The operating cost was 151 million yuan, an increase from 131 million yuan in the same period last year. The net profit was 316 million yuan, up from 235 million yuan in the same period last year. The gross profit margin was 80.52%, down from 84.19% in the same period last year. The net interest rate was 40.72%, up from 28.4% in the same period last year. Return on equity (ROE) was 5.66 per cent, up from 4.35 per cent at the end of last year.
In terms of cash flow, the net cash flow generated by Shuanglu Pharmaceutical's operating activities in the third quarter of 2023 was 224 million yuan, down from 273 million yuan in the same period last year. Cash inflows from operating activities totaled 788 million yuan, down from 934 million yuan in the same period last year. Cash outflow from operating activities totaled 563 million yuan, down from 662 million yuan in the same period last year.
To sum up, Shuanglu Pharmaceutical Co., Ltd. is generally stable in the third quarter of 2023. The asset-liability ratio decreased and the net profit increased significantly, but the net cash flow decreased. This may be due to the fact that some regional companies changed their products to base price shipments and the continuous price reduction of major products by the national collection bidding had a certain impact on the company, resulting in a 6.09% drop in operating revenue compared with the same period last year. In addition, the fair value of other non-current financial assets held by the company has changed, and the income from fair value changes has increased by 577.08% over the same period last year, but decreased by about 23.93 million yuan in the reporting period.
For investors, Shuanglu Pharmaceutical Co., Ltd. has a stable performance, a significant increase in net profit and a decline in asset-liability ratio, showing a good operating condition. However, the decrease in net cash flow may put some pressure on the company's operations. Therefore, when making investment decisions, investors should comprehensively consider the financial indicators and operating conditions of the company.
This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.